Screener / SEC EDGAR /CIK 0000885590 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Pharmaceuticals

Bausch Health Companies Inc. BHC

Compare with peers Embed
SEC comment letters, last 20 years

2 reviews of BHC's filings by SEC staff

UPLOAD and CORRESP
Reviews 2 latest letter Aug 8, 2019
Questions asked 19 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 4 UPLOAD
  2. 2. Questions in them 19 numbered comments
  3. 3. Company replies 4 CORRESP
  4. 4. Reviews closed 2 of 2 closing letter

Half the closed reviews took 110 days or less from the first letter to the closing letter.

Form 10-K for the Fiscal Year Ended December 31, 2018

2019-08-08 to 2019-09-13 · 1 question · 1 letter from the SEC, 1 from the company
Review closed 2019-09-13
RevenueRussia and Ukraine
General
SEC asked
In its letter dated August 10, 2016, Valeant Pharmaceuticals International, Inc. stated that it had sold products into Sudan and Syria. As you know, Sudan and Syria are designated by the U.S. Department of State as state sponsors of terrorism, and are subject to U.S. economic sanctions and/or export controls. You do not include disclosure about Sudan and Syria in the Form 10 -K.
Rest of the question

Please describe to us the nature and extent of your past, current and anticipated contacts with Sudan and Syria since the August 2016 letter, including contacts with their governments, whether through subsidiaries, distributors, or other direct or indirect arrangements. Please also discuss the materiality of the contacts, in quantitative terms and in terms of qualitative factors that a reasonable investor would deem important in making an investment decision. Tell us the approximate dollar amounts of any revenues, assets and liabilities associated with Sudan and Syria for the last three fiscal years and the subsequent interim period. Address the potential impact of the investor sentiment evidenced by divestment and similar initiatives that have been directed toward companies that have operations associated with U.S.- designated state sponsors of terrorism.

BHC answered
We respectfully acknowledge the Staff’s comment. As indicated in our letter to you of August 10, 2016 (the “Prior Letter”), at that time, the Company had minimal sales into Syria and Sudan, all of which were made in accordance with applicable laws and under the requisite licenses. As further described below, since the Prior Letter, the Company’s contacts with Syria and Sudan have continued to be minimal, involving minimal sales of certain of our products by a wholly-owned subsidiary (located outside of Syria and Sudan) to third-party distributors in Syria and Sudan for medicinal and
Rest of the answer

health-related purposes. All of these sales were (and any future sales will be) conducted in accordance with U.S. and other applicable laws, as well as in accordance with the Company’s own corporate policies and global trade controls that ensures compliance with applicable economic sanctions. As further described below, we operate under the requisite U.S. Department of Treasury, Office of Foreign Assets Control (OFAC) and U.S. Department of Commerce, Bureau of Industry and Security (BIS) licenses in these countries. As regards our third-party distributors in Syria and Sudan, all such third-party distributors are separate legal entities in which the Company and its affiliates have no direct or indirect equity interest or other interest and over which the Company and its affiliates have no control. In accordance with our internal policies and practices, prior to engaging third-party distributors in Syria and Sudan, the Company conducts due diligence on each such distributor and, on an ongoing basis (through certifications and contractual clauses), the Company confirms that such third-party distributors conduct themselves in compliance with applicable laws (including applicable economic sanctions and export laws and regulations).

Bausch Health and its affiliates do not have any physical presence, operations or employees in either Syria or Sudan.

Syria: The Company sells certain of its ophthalmic surgical products to one approved third-party distributor in Syria, with which the Company’s subsidiary has a distribution agreement. All sales of products into Syria are made under a license issued by the U.S. Department of Commerce, Bureau of Industry and Security (BIS) and under a general license issued by the U.S. Department of Treasury, Office of Foreign Assets Control (OFAC). As further described on Appendix A hereto, revenue from sales into Syria was minimal during 2016, 2017, 2018 and the subsequent interim period (revenue from sales was, in the aggregate, approximately [***] for this entire period) and represented an immaterial portion of total Company revenue for the applicable period (less than 0.001% of total consolidated revenues). The Company has no assets or liabilities in Syria. To the best of the Company’s knowledge after due inquiry, the Company and its affiliates have no agreements, arrangements or other contacts, whether direct or indirect, with the government of Syria or entities known to be controlled by the government of Syria, other than (i) interactions that are ordinarily incidental and necessary to comply with applicable local requirements relating to the sale of medical products, such as the provision of information and documentation in support of product registrations and approvals, which is done by our third-party distributor, and (ii) as relates to certain intellectual property filings, as further described below.

Sudan: The Company sells certain of its pharmaceutical products, including certain dermatological products, to one approved third-party distributor in Sudan. The Company’s distribution agreement with this distributor has expired and the Company is in the process of negotiating the terms of a new agreement, which we anticipate will be entered into in the near future. In addition, the Company is negotiating an agreement with an additional distributor in Sudan, but there have been no sales to this distributor to date. All sales of products into Sudan are made under a general license issued by the U.S. Department of Treasury, Office of Foreign Assets Control (OFAC). As further described on Appendix A hereto, revenue from sales into Sudan was minimal during 2016, 2017, 2018 and the subsequent interim period (revenue from sales was, in the aggregate, approximately [***] for this entire period) and represented an immaterial portion of total Company revenue for the applicable period (less than 0.01% of total consolidated revenues). The Company has no assets or liabilities in Sudan. To the best of the Company’s knowledge after due inquiry, the Company and its affiliates have no agreements, arrangements or other contacts, whether direct or indirect, with the government of Sudan or entities known to be controlled by the government of Sudan, other than (i) interactions that are ordinarily incidental and necessary to comply with applicable local requirements relating to the sale of pharmaceutical products, such as the provision of information and documentation in support of product registrations and approvals, which is done by our third-party distributor, and (ii) as relates to certain intellectual property filings, as further described below.

Contacts with the Government - Intellectual Property Filings: During 2016, 2017, 2018 and 2019, to the best of the Company’s knowledge, after due inquiry, the Company has not made any new filings of its intellectual property (trademarks or patents) in either Syria or Sudan. However, during this period, the Company paid renewal fees in Syria and Sudan (to the applicable intellectual property offices) for the renewal of certain trademarks for certain of its products in those countries. The renewal fees paid were minimal and immaterial.

The contacts in Syria and Sudan described above are not material to the Company, either individually or in the aggregate. Appendix A hereto sets out the revenue from sales into Syria and Sudan for fiscal years 2016, 2017, 2018 and the subsequent interim period (the first and second quarters of fiscal year 2019), in both US dollars and as a percentage of the total consolidated revenue of the Company. As Appendix A clearly shows, the revenues from our sales into Syria and Sudan are de minimis and quantitatively immaterial to the Company. Similarly, the costs to administer our distribution arrangements in Syria and Sudan are also immaterial, as are the fees paid with respect to our intellectual property filings in Syria and Sudan. From a qualitative perspective, the purpose and nature of these transactions have been medicinal and health-related in nature. All transactions were conducted in full compliance with U.S. and other applicable laws and the Company operates under the necessary OFAC and BIS licenses to conduct such transactions. All sales were in arm’s-length transactions to third-party distributors, each of whom was investigated and approved in accordance with our internal policies and practices. To the best of the Company’s knowledge after due inquiry, other than minimal intellectual property filings in these countries and ordinary, incidental interactions performed by our third-party distributors to facilitate the sale of products in these countries, the Company and its affiliates have no agreements, arrangements or other contacts, whether direct or indirect, with the governments of either Syria or Sudan or entities known to be controlled by such governments. In conclusion, these sales into Syria and Sudan are not material to our past, current or anticipated future operations, either on a quantitative or qualitative basis.

We do not believe that these minimal and de minimis sales into Syria and Sudan, all of which were conducted in compliance with law, raise concerns for an adverse investor sentiment or are factors that a reasonable investor would deem important in making an investment decision in respect of the Company’s securities. Furthermore, the Company does not believe that these transactions, nor any potential associated reputational risk, represent a material investment risk to security holders. The Company also believes that these transactions would not have a material impact on its reputation or share value. Accordingly, the Company believes that no specific reference was needed in our annual report on Form 10-K for the fiscal year ended December 31, 2018. We will continue to monitor our activities in Syria and Sudan and will include appropriate disclosures in our SEC filings if we later conclude that such disclosure is required.

If you require additional information, please feel free to contact me at 908-541-5450.

Yours Truly,

/s/ Sam Eldessouky

Sam Eldessouky

SVP, Controller and Chief Accounting Officer cc: Suzanne Hayes, Assistant Director, Division of Corporation Finance

Pradip Bhaumik, Special Counsel, Division of Corporation Finance

Paul Herendeen, EVP, Chief Financial Officer of Bausch Health Companies Inc.

Christina Ackermann, EVP, General Counsel of Bausch Health Companies Inc.

Appendix A

Revenue from Sales into Syria and Sudan for Fiscal Years 2016, 2017 and 2018 and Year-to-Date Fiscal Year 2019 (First and Second Quarters)

Revenue for 2016

Revenue for 2017

Revenue for 2018

Revenue for YTD 2019 (1st and 2nd quarters)

Syria

Revenue for Syria

[***]

Total Consolidated Company Revenue

Revenue for Syria as Percentage of Total Consolidated Company Revenue

Sudan

Revenue for Sudan

Revenue for Sudan as Percentage of Total Consolidated Company Revenue

Read in the reply

Also in this review: closing letter, 2019-09-13

Form 10-K for the Fiscal Year Ended December 31, 2015

2016-07-13 to 2016-10-31 · 18 questions · 3 letters from the SEC, 3 from the company
Review closed 2016-10-31
Non-GAAP measuresIncome taxesRevenueResults discussion (MD&A)Liquidity and cashRussia and UkraineInventoryAcquisitionsRisk factorsGoodwill and impairmentCritical estimatesControlsDebtLegal and contingencies
General
SEC asked (1)
You state on page 4 that you sell branded generic pharmaceutical products, branded pharmaceuticals, over-the-counter products and medical devices in the Middle East, a region that includes Syria. We note on your website a press release dated October 9, 2014, announcing that you acquired MedPharma Pharmaceutical & Chemical Industries.
Rest of the question

We are aware of publicly available information indicating that MedPharma operates in Sudan. Syria and Sudan are countries designated by the U.S. Department of State as state sponsors of terrorism and subject to U.S. economic sanctions and export controls. You do not include disclosure about contacts with Syria or Sudan. Please describe to us the nature and extent of any past, current and anticipated contacts with Syria and Sudan, whether through direct or indirect arrangements. You should describe any products or services you have provided into Syria and Sudan, directly or indirectly, and any agreements, commercial arrangements or other contacts you have had with the governments of those countries or entities they control.

BHC answered
Mr. Jim B. Rosenberg

Securities and Exchange Commission region that includes Syria. We note on your website a press release dated October 9, 2014, announcing that you acquired MedPharma Pharmaceutical & Chemical Industries. We are aware of publicly available information indicating that MedPharma operates in Sudan. Syria and Sudan are countries designated by the U.S. Department of State as state sponsors of terrorism and subject to U.S. economic sanctions and export controls. You do not include disclosure about contacts with Syria or Sudan.
Rest of the answer

Please describe to us the nature and extent of any past, current and anticipated contacts with Syria and Sudan, whether through direct or indirect arrangements. You should describe any products or services you have provided into Syria and Sudan, directly or indirectly, and any agreements, commercial arrangements or other contacts you have had with the governments of those countries or entities they control.

We respectfully acknowledge the Staff’s comment. The Company requested that we inform you that it complies with U.S. economic sanctions laws and export regulations applicable to its commercial activities, including those relating to Syria and Sudan. As further described below, the Company has had minimal sales of certain of its products into Syria and Sudan, all of which were conducted in accordance with U.S. and other applicable laws, including (where required) appropriate licenses issued by the applicable U.S. regulatory authorities. Sales into Syria were less than $100,000 and into Sudan were less than $500,000, in each case for the year ended December 31, 2015. To the best of the Company's knowledge after due inquiry, neither the Company nor any of its subsidiaries has any agreements, commercial arrangements or contacts with the government of Syria or Sudan or with any entities known to be controlled by the government of Syria or Sudan.

Sudan: In 2015 and 2016, the Company (through its subsidiary, MedPharma Pharmaceutical & Chemical Industries LLC) had limited sales of certain of its pharmaceutical products (including certain dermatological products) to a third party distributor in Sudan. The Company believes that all such sales were made pursuant to appropriate licenses issued by the U.S. Department of the Treasury, Office of Foreign Assets Control (OFAC).

Syria: In 2013, 2014, 2015 and 2016, the Company (through its subsidiaries, Bausch + Lomb OPS B.V. and Technolas Perfect Vision GmbH) had limited sales of certain of its ophthalmic surgical products to a third party distributor in Syria. The Company believes that such sales either (i) were made pursuant to a license issued by the U.S. Department of Commerce, Bureau of Industry and Security (BIS), or (ii) did not require a BIS license for export to Syria due to the origin of such products (or the origin of such products’ components).

The Company requested that we inform you that any future dealings with these countries will also be conducted in accordance with U.S. and other applicable laws, including, where required, appropriate licenses issued by OFAC, BIS or other applicable U.S. regulatory authorities. Although the Company currently does not believe that the nature of the products and sales described above constitute a material risk to the Company or investors, it will continue to monitor its activities relating to Sudan and Syria and will include appropriate disclosure in its SEC filings if it later concludes that such disclosure is required.

Management's Discussion and Analysis of Financial Condition and Results of Operations U.S. Healthcare Reform, page 43

Read in the reply
Management’s Discussion and Analysis of Financial Condition and Results of Operations · U.S. Healthcare Reform, page 43
SEC asked (2)
In addition to your disclosure in the last paragraph of this section that legislative action may lead to price controls, you disclose in risk factors on page 14 that your prices are under scrutiny and on page 20 that you may reduce some prices.
Rest of the question

On pages 43 and 47 of your March 31, 2016 Form 10-Q you announce the formation of a new Patient Access and Pricing Committee that has already established enhanced rebate programs for two of your products. Where a trend, demand, commitment, event or uncertainty is known, management must make two assessments. Refer to Section III. B of MD&A interpretive release 33-6835. Please provide us your analysis of these assessments supporting your conclusion that disclosure of the expected effects on future financial condition and results of operations regarding the uncertainty of maintaining current revenue levels is not necessary.

BHC answered
We respectfully acknowledge the Staff’s comment. The Company, in its preparation of the December 31, 2015 Form 10-K and the March 31, 2016 Form 10-Q, did consider the effect of the implemented and potential price actions on its revenue trends to determine the extent of forward-looking disclosure required in the MD&A. Specifically, the Company’s analysis of the two assessments pursuant to the requirements under Section III.
Rest of the answer

B of MD&A interpretive release 33-6835 is summarized as follows:

Assessment for purposes of the 2015 Form 10-K

Implemented or potential price actions considered:

·

No implemented price actions as of the date of filing of the Company’s 2015 Form 10-K

Potential price actions include:

(a)

Anticipated price reduction or other anticipated pricing actions (such as discounts or rebates) on the Company’s Isuprel® and Nitropress® products as a result of a number of factors, including input from various constituencies of the Company (including group purchasing organizations, insurance companies, hospitals, physicians and patients) and consideration of issues raised during Congressional inquiries;

(b)

Anticipated price reduction of certain branded prescription-based dermatological and ophthalmologic products that would be sold through the fulfillment programs with Walgreens by, on average, approximately 10 percent;

(c)

Potential price controls resulting from legislative action; and

(d)

The Company’s intentions with respect to the cessation of or limitation on pricing increases for certain products.

Analysis of the two assessments:

Assessments

Analysis

(1) Is the known trend, demand, commitment, event or

Management concluded Assessment (2) was required for each of the potential price actions in uncertainty likely to come to fruition? If management determines that it is not reasonably likely to occur, no disclosure is required.

items (a), (b) and (d) above, as they were reasonably likely to occur. With respect to the potential price action described in (c) above, the Company was unable to determine whether or not new legislation was reasonably likely to occur.

(2) If management cannot make that determination, it must evaluate objectively the consequences of the known trend, demand, commitment, event or uncertainty, on the assumption that it will come to fruition. Disclosure is then required unless management determines that a material effect on the registrant's financial condition or results of operations is not reasonably likely to occur.

Management evaluated each of the potential price actions and concluded as follows:

(a) Potential price reductions on Isuprel® and Nitropress®

– Management did not anticipate the potential effect from the price reductions on Isuprel® and Nitropress® to be material to the overall revenue trend as both products are near the end of their patent exclusivity (for which the Company disclosed the anticipated timing of the potential generic competition for these two products under “Competition” within Item 5 of the 2015 Form 10-K). Total sales of Isuprel® were approximately $224 million and of Nitropress® were approximately $219 million for the year ended December 31, 2015, each representing approximately 2% of total revenues for that period. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

(b) Price reduction on certain dermatological and ophthalmologic products

– Management did not anticipate the potential price reduction would have a material impact on the Company’s overall revenue trend as management anticipated that the impact of the price reduction would be offset by the impact of the increased volume (which is disclosed in the Selected Financial Information within the MD&A of the 2015 Form 10-K). In addition, the relationship with Walgreens began in January 2016, and net sales recognized through Walgreens represented approximately 3% of the Company’s total consolidated revenue for each of the second quarter and first half of 2016. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

(c) Potential price controls resulting from legislative actions

– Given this factor was not under management’s control, the Company did not have a basis to evaluate the impact that such actions would have on its overall revenue trend. Accordingly, no disclosure of a trend was deemed necessary. Please note that the Company did refer to the potential impact of legislative actions in the Forward Looking Statements legend (see pages iv – vi), as well as the Risk Factors (see pages 14-15 and 30), in the Company's Form 10-K for the year ended December 31, 2015.

(d) Intentions with respect to ceasing or limiting price increases on certain products.

The Company expected that any potential pricing action (other than those imposed by legislative actions) would be made strategically based on, among other things, a price-volume assessment. Management did not anticipate, at the time of the filing of the 2015 Form 10-K, that any potential pricing action would have a material impact on the Company’s overall revenue trend. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

Assessment for purposes of the March 31, 2016 Form 10-Q

Implemented price actions as of the date of filing of the Company’s March 31, 2016 Form 10-Q

Enhanced rebate program on the Company’s Isuprel® and Nitropress® products implemented in May 2016 and confirmation of no future price increases for these two products.

Anticipated price reduction of certain branded prescription-based dermatological and ophthalmologic products that would be sold through the fulfillment programs with Walgreens by, on average, approximately 10 percent;

The Company’s intentions with respect to the cessation of or limitation on pricing increases for certain products, as well as the Company's formation of a new Patient Access and Pricing Committee in May 2016.

(1) Is the known trend, demand, commitment, event or uncertainty likely to come to fruition? If management determines that it is not reasonably likely to occur, no disclosure is required.

Management concluded Assessment (2) was required for each of the implemented and potential price actions listed in items (a), (b) and (d) above, as they were reasonably likely to occur. With respect to the potential price action described in (c) above, the Company was unable to determine whether or not new legislation was reasonably likely to occur.

(2) If management cannot make that determination, it must evaluate objectively the consequences of the known trend, demand, commitment, event or uncertainty, on the assumption that it will come to fruition. Disclosure is then required unless management determines that a material effect on the registrant's financial condition or results of operations is not reasonably likely to occur.

Management’s evaluation for the potential price actions in items (a), (b) and (d) is consistent with that conducted for purposes for the 2015 Form 10-K and concluded no disclosure on a quantitative basis of any trend was necessary. Please note that the MD&A of the Form 10-Q for the three months ended March 31, 2016 did contain disclosure that a new Patient Access and Pricing Committee was formed in 2016 and would be responsible for pricing of the Company's drugs. The disclosure also noted that an enhanced rebate program relating to the pricing of Nitropress® and Isuprel® products for hospitals was implemented pursuant to a recommendation of the Patient Access and Pricing Committee and that the Patient Access and Pricing Committee confirmed that there would be no further price increases for these two products or reductions to the discount levels in the rebate program. Further, the Company anticipated that such committee would implement or recommend additional price changes and/or new programs to enhance patient access to the Company's drugs, and that such pricing changes and programs could affect the averaged realized prices for the Company's products and may have a significant impact on revenue trends (see pages 47-48 of the Form 10-Q for the three months ended March 31, 2016).

With respect to the enhanced rebate program for

Isuprel® and Nitropress® and cessation of future price increases for these two products, management estimated the effect of the enhanced rebate program and the cessation of price increases, including consideration of the timing of generic entry, and concluded that it did not anticipate the lower realized price would have a material impact on the Company’s overall revenue trend. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Critical Accounting Policies and Estimates · Goodwill, page 70
SEC asked (3)
Please tell us how you factored your potential product price decreases in your assessment that hypothetical 15% decreases in the fair values of each of your reporting units would not have triggered additional impairment testing during the fourth quarter of 2015 or as of March 31, 2016 as disclosed on page 24 of your March 31, 2016 Form 10-Q.
Rest of the question

In addition, please tell us how you considered these potential product price decreases in your impairment analyses for individual product-related intangible assets.

BHC answered
We respectfully acknowledge the Staff’s comment. In conducting the Company’s annual goodwill impairment testing during the fourth quarter of 2015 and interim goodwill impairment testing as of March 31, 2016, management had considered known or anticipated price reductions in estimating the fair value of each reporting unit. The implemented or potential price decreases disclosed in the Company’s Form 10-K for the year ended December 31, 2015 and Form 10-Q for the three months ended March 31, 2016 primarily relate to a portfolio of products that are part of the U.S. Reporting Unit.
Rest of the answer

As part of the goodwill impairment test for the U.S. Reporting Unit, forecasted revenue for the impacted products was determined taking into consideration, among various other factors, known product price decreases. In addition, for the impact of any future uncertainties, which would include potential future price decreases, management incorporated the potential impact by applying a higher discount rate to discount the cash flows of each reporting unit in determining the fair value. Because fair value estimates involve significant judgment, management, as a measure of conservatism, also applied a hypothetical 15% decrease in the fair value of each of the reporting unit to capture any unanticipated factors that could negatively affect the reporting unit’s fair value. As disclosed in the Company’s 2015 Form 10-K and March 31, 2016 Form 10-Q, the hypothetical 15% decrease did not trigger additional impairment testing.

In respect of impairment testing for the product-related intangible assets, an impairment analysis was completed for each intangible asset to which potential price decreases may apply. The impairment analysis compared the sum of undiscounted cash flows for each product to its net book value pursuant to ASC 350-30, General Intangibles Other than Goodwill. The forecast revenue used as the basis for the undiscounted cash flow analysis assumed, among various other factors, known and potential price reductions. For each product subject to impairment testing during the fourth quarter of 2015 and as of March 31, 2016, management concluded that no impairment resulted as the sum of undiscounted cash flows exceeded the product’s net book value. While no impairment resulted, the Company did include in its forward-looking statements legend (see page iv and vi) and risk factors (see risk factors in Form 10-K for the year ended December 31, 2015 that are referenced in the Form 10-Q for the three months ended March 31, 2016) disclosure related to potential impairments.

Read in the reply
Item 9A. Controls and Procedures · Management’s Report on Internal Controls Over Financial Reporting, page 79
SEC asked (4)
You disclose that your tone at the top material weakness may have been a contributing factor in sales efforts that resulted in the granting of discounts and extended payment terms and inventories above target levels at certain distributors in Russia and Poland.
Rest of the question

Please demonstrate to us why these sales efforts did not result in a material misstatement of your financial statements as you disclose in the last bullet on page 79. In your response, explain to us why these activities did not result in a material misstatement when it appears from the disclosure in the first full paragraph on page 48 that you expect 2016 revenues will be reduced by approximately $50 million to bring the wholesaler inventory levels in Russia and Poland from the current four to five months down to the targeted level of less than three months.

BHC answered
We respectfully acknowledge the Staff’s comment. The Company asked us to inform you that as described on page 79 of the Company’s Form 10-K for the year ended December 31, 2015, management concluded that the "tone at the top" material weakness may have been a contributing factor in sales efforts that resulted (i) in inventories above target levels at certain distributors in Russia and Poland at various quarter ends and (ii) in incentivizing distributors through the granting of discounts and extension of certain payment terms to make purchases at certain quarter ends.
Rest of the answer

The Company has concluded that these sales efforts did not result in a revenue recognition misstatement, as further described below. The Company uses certain guidelines to effectively manage its business and operational risks, which include target inventory levels in the distribution channels for certain key markets. These target inventory levels are not set to be a guideline for revenue recognition but rather used as a way to monitor the level that the Company believes is appropriate to manage their business in such country.

In connection with the preparation of its financial statements for the year ended December 31, 2015, the Company conducted a review of the appropriateness of revenue recognition for sales transactions in Russia and Poland. This was done in light of additional sales discounts and extended payment terms being offered to certain of its customers, which contributed to the higher level of in channel inventory in those countries. Each of the revenue recognition criteria in ASC 605 Revenue Recognition / SEC Staff Accounting Bulletin Topic 13 was analyzed and the Company’s assessment of each criterion is summarized below:

(1)

Persuasive evidence of an arrangement exists

The Company concluded that this criterion was met and noted that all revenue arrangements were evidenced at the time the sales were recorded by executed agreements, purchase orders, amendments/annexes and/or email confirmations, which are consistent with customary business practices in those countries.

(2)

Delivery has occurred or services have been rendered

The Company concluded that this criterion was met as revenue was not recognized until the products had been delivered and title and risk of loss had passed pursuant to the terms of the arrangement,

(3)

The seller's price to the buyer is fixed or determinable

The Company evaluated its ability to assert this criterion in light of the sales discounts and/or rebates being offered to certain of its customers in Russia and Poland. While the majority of the sales discounts and/or rebates were fixed at the time of the sales transactions, there were certain volume-based sales incentives being offered. For those volume-based sales incentives, management concluded that it has sufficient experience to estimate the amounts of sales discounts and/or rebates based on historical trends and the promotional/rebate programs in place.

In addition, because there was a higher than target level of inventory in the distribution channels in both countries, the Company did consider the risk of having to provide future concessions to the customers and thereby, impairing its ability to assert that this revenue recognition criterion was met. After considering the contractual terms with the customers and the Company’s historical practices, it was concluded that the higher inventory level would not affect the Company’s assertion of this criterion. The customers do not have a general right of return under the contracts and the Company has not established a practice of accepting returns and does not intend to do so in the future. Additionally, the Company does not have any explicit or implicit requirements to provide further concessions or assistance to assist with the customers’ downstream sales. Accordingly, the Company concluded this criterion was met.

(4)

Collectability is reasonably assured

In evaluating this criterion, the Company considered past collection experience, particularly with customers for which it had provided extended payment terms. Based on its historical experience, with each customer, and evaluation of the customer’s current financial status / ability to pay, the Company concluded this criterion was met.

As part of its ongoing procedures, the Company monitors its receivables in Poland and Russia and notes that the receivables outstanding as of December 31, 2015 were substantially collected (97%) as of June 30, 2016.

Based on the foregoing, the Company concluded revenue was appropriately recognized for sales in Russia and Poland.

The Company’s disclosure of the expected revenue reduction resulting from reducing the inventory in the channel in the future was to provide readers with forward looking information about the expected impact of the Company’s planned actions. Given the Company’s plan to bring down the wholesaler inventory levels in Russia and Poland to the targeted level of less than three months, management believed that it would be useful to inform the readers of the potential impact as Poland and Russia represents a significant portion of the Company’s Emerging Markets segment.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Consolidated Statements of Shareholders’ Equity, page F-8
SEC asked (5)
Please explain to us why you reflect a reduction to additional paid-in capital for employee withholding taxes related to share based awards. Also explain to us why the apparent payment of these taxes is a financing activity on your cash flow statements on page F-9. In your response, explain why these withholding taxes are apparently not collected from employees.
Rest of the question

Reference for us the authoritative literature you rely upon to support your accounting.

BHC answered
We respectfully acknowledge the Staff’s comment. The reduction to additional paid-in-capital for employee withholding taxes related to share based awards is a result of net share settlement for certain of the Company’s share based awards. The Company’s equity incentive plan permits net share settlement whereby the Company withholds a number of vested shares upon settlement of restricted stock units or exercise of stock options to satisfy the minimum tax withholding obligation.
Rest of the answer

Said another way, the withholding taxes that are due from the employee are collected by the Company via the share withholding. The number of vested shares withheld is determined based on the fair market value of a share of the Company’s common stock on the date of settlement or exercise.

The shares withheld for minimum tax withholding are, in effect, repurchases of vested shares at fair market value by the Company on the date of settlement or exercise and management accounts for the share repurchase in accordance with ASC 718-20, Awards Classified as Equity. Pursuant to ASC 718-20-35-7, the cash settlement of an award is the repurchase of an equity instrument. Accordingly, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date.

With respect to the cash flow presentation, we note that Accounting Standards Update ("ASU") 2016-09 Compensation –Stock Compensation (Topic 718) – Improvements to Employee Share-Based Payment Accounting addresses this topic by requiring an employer to classify the cash paid to a taxing authority on the employee’s behalf when directly withholding shares for tax-withholding purposes as a financing activity in the statement of cash flows. This ASU is not yet effective and has not been adopted by the Company. However, this guidance is consistent with Valeant's current accounting policy. It should be noted that the ASU provides that current

GAAP does not include specific guidance about the cash flow classification for those transactions.

Management considers the remittance of employee withholding taxes to the tax authorities on the employees’ behalf is “in substance” consideration paid for repurchase of vested shares from the employees. Accordingly, management believed it would be appropriate to classify such cash outflows as a financing activity.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Notes to Consolidated Financial Statements · Note 4: Acquisitions, page F-14
SEC asked (6)
Throughout this note you disclose that the amounts of the fair values of the assets acquired and liabilities assumed as of the acquisition dates for your various acquisitions are provisional and subject to change. Please tell us your consideration of disclosing the specific assets and liabilities for each acquisition for which the initial accounting is incomplete as required by ASC 805-20-50-4Ab.
BHC answered
We respectfully acknowledge the Staff’s comment. The Company did consider the requirement under ASC 805-20-50-4Ab when making disclosure of its business combinations. In the 2015 Form 10-K, the Company provided separate disclosure for the three material business combinations that were consummated during 2015 and aggregated disclosure for the remaining 2015 business combinations.

Of the three more significant business combinations, two were consummated in the fourth quarter of 2015 (namely, Amoun Pharmaceutical Company S.A.E. and Sprout Pharmaceuticals, Inc.).
Rest of the answer

Due to the timing of those transactions, all amounts recorded were provisional. These provisional amounts are subject to change when and if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date. The Company monitors these provisional amounts quarterly and makes the necessary changes, when and if applicable.

With respect to the acquisition of Salix (consummated on April 1, 2015), the Company finalized its purchase accounting in the fourth quarter of 2015 and therefore, the purchase price allocation as disclosed was final. For the remaining 2015 business combinations, the Company believes its disclosure on page F-31 satisfies the requirement under ASC 805-20-50-4Ab.

In prior reporting periods where the measurement process for an acquisition was incomplete, the Company did address the requirement of ASC 805-20-50-4Ab. Please refer to the Company’s disclosure of the acquisition of Salix in Note 3 of the September 30, 2015 consolidated financial statements (page 8 of the Company's Form 10-Q for the nine months ended September 30, 2015) and the Company’s disclosure of the acquisitions of Amoun and Sprout in Note 4 of the March 31, 2016 consolidated financial statements (pages 11-13 of the Form 10-Q for the three months ended March 31, 2016) where the Company specifically identified the assets and liabilities that were provisional.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 18: Income Taxes, page F-70
SEC asked (7)
Please provide us additional information that clarifies what the following reconciling items in your rate reconciliation table on page F-71 represent and explains why each has the following identified impact on your effective tax rate for the relevant period:  Adjustment to tax attributes with decreases from the effective tax rate of $87.1 million in 2015 and $32.3 million in 2014;  Canadian dollar foreign
Rest of the question

exchange gain for Canadian tax purposes with an increase from the effective tax rate of $173.6 million in 2015;  Change in valuation allowance related to foreign tax credits and net operating losses with an increase from the effective tax rate of $114.0 million in 2015; and  Tax benefit on intra-entity transfers with decreases from the effective tax rate of $374.9 million in 2015 and $147.3 million in 2014.

BHC answered
We respectfully acknowledge the Staff’s comment. The Company’s response with respect to each of the line items on the rate reconciliation for the periods presented are as follows:

“Adjustments to tax attributes” is primarily the incremental change to tax attributes such as foreign tax credits, and research and development credits for current year activity as well as any reduction due to limitations placed upon the use of such attributes such as change of control limitations or time limitations.
Rest of the answer

The changes in the tax attributes have a permanent effect on the tax position of the Company.

“Canadian dollar foreign exchange gain for Canadian tax purposes” represents the Canadian tax effects on the U.S. Dollar denominated debt held by the Company. As you are aware, the Company is a Canadian company but has the U.S. Dollar as its functional currency. For Canadian tax purposes, its functional currency is the Canadian dollar. As a consequence of having different functional currencies for financial reporting and tax basis accounting, the foreign currency exchange impact on the settlement of its obligations results in a permanent tax expense/benefit.

“Change in valuation allowance related to foreign tax credits and net operating losses” is the expense impact associated with changes in the valuation allowance on deferred tax assets not within Canada. These are primarily comprised of those valuation allowances found on foreign tax credits in the U.S. and net operating losses in various international locations.

“Tax benefit on intra-entity transfers” is comprised of net tax benefits to the Company's tax provision related to the transfer of property – including intellectual property of affiliates. This includes the impacts under ASC740-10-25-3(e) which requires the deferral of the tax impacts of intra-entity transfers on a consolidated financial statement.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 18: Income Taxes, page F-70
SEC asked (8)
Also regarding your rate reconciliation on page F-71, please tell us why it is appropriate to reflect the change in valuation allowance on Canadian deferred tax assets in the same reconciling item as the impact of tax rate changes. In your response separately quantify the impact of each of these items for each of the last three years.
BHC answered
We respectfully acknowledge the Staff’s comment. In order to comply with the disclosure requirements under ASC 740-10-50-12 and Regulation S-X, Rule 4-08(h), the Company has separately disclosed the significant items that reconcile the reported amount of income tax expense for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pre-tax income (loss).
Rest of the answer

As the change in valuation allowance is one of the more significant reconciling items, the Company has deemed itemizing the significant components of the change in valuation allowance would provide more meaningful information to the readers of the financial statements (e.g., the Company separately presents changes in valuation allowances related to non-Canadian deferred tax assets (see response to Comment 7 above) and changes in valuation allowances related to Canadian deferred tax assets). Given the change in valuation allowance related to tax rate changes (which resulted from changes in the level of the Company’s operations in different tax jurisdictions) is typically the smallest component of the total change in valuation allowance, the Company has historically presented this component with the change in valuation allowance on its Canadian deferred tax assets in its tax rate reconciliation disclosure.

As requested by the Staff, the table below provides a breakdown of the change in valuation allowance on Canadian deferred tax assets and tax rate changes:

2015

2014

2013

Canadian VA

229.4

234.8

128.9

Rate Change VA

-

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Selected Financial Information · Financial Performance; Change in Revenues, page 47
SEC asked (9)
Please tell us your consideration for disclosing the existence of negative average selling prices associated with your Walgreens fulfillment agreement and the sales force disruptions for Xifaxan as identified in your June 7, 2016 earnings conference call and their impact on your expected revenue for 2016.
Rest of the question

As your expected revenue for 2016 appears to be less than 2015 revenues, it appears that these items, as well as others, may be factors contributing to a known trend or uncertainty.

BHC answered
to the Staff’s Comment, the Company intends to continue to consider known trends and uncertainties and provide appropriate MD&A disclosure in future filings.
Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated June 7, 2016 · Non-GAAP Information, fourth page
SEC asked (10)
Please reconcile for us the last sentence in the first paragraph of this section and your December 18, 2015 response to comment 4 of our December 4, 2015 letter indicating why you do not present guidance on a GAAP basis with the statement made by your Chief Executive Officer in the closing remarks to your June 7, 2016 earnings conference call indicating that you maintain GAAP projections.
BHC answered
We respectfully acknowledge the Staff's comment. On the Company's June 7, 2016 earnings conference call, Valeant's Chief Executive Officer did not intend to indicate that the Company currently has or utilizes projections of GAAP net income. Rather, the Company does have projections of GAAP total revenue (which it periodically makes publicly available).
Rest of the answer

In addition, the Company is able to forecast with reasonable certainty particular adjustments (such as amortization) that would be used to calculate GAAP net income, but was not able to project all adjustments necessary to project GAAP net income. As a result, in the earnings release furnished on Form 8-K on June 7, 2016, the Company disclosed that they do not provide GAAP guidance due to the inherent difficulty in forecasting and quantifying certain amounts that would be necessary to determine the GAAP guidance.

In periods where there are not expected to be significant acquisitions or divestitures, the Company believes it might have a basis for forecasting the GAAP equivalent for certain costs, such as amortization, that would otherwise be treated as non-GAAP to calculate projected net income (loss). However, because other deductions (e.g., restructuring, gain or loss on extinguishment of debt and litigation settlements) used to calculate projected GAAP net income (loss) could vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. However, the Company informed us that it will continue to evaluate its ability to provide projected GAAP net income (loss) and, should it make a determination that it can adequately forecast projected net income (loss) on a GAAP basis, it would intend to provide such guidance.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated April 29, 2016 · Reconciliation of GAAP EPS to Adjusted EPS Non-GAAP, Table 2b
SEC asked (11)
It appears from the non-GAAP adjustments presented in this table that your non-GAAP effective tax rates were 20.0% in 2013, 9.4% in 2014 and 22.9% in 2015. Please explain to us why the rate in 2014 is so much lower than the rates in 2013 and 2015.
Rest of the question

In your response, clarify for us how you assess tax attributes, including your assessment of valuation allowances on deferred tax assets, for non-GAAP tax provision purposes under the hypothetical profit scenarios inherent in your non-GAAP presentation.

BHC answered
The non-GAAP tax rate in 2014 was lower, as compared to 2013 and 2015, as a result of the exclusion of a gain, and the associated tax effect, on a sale of certain assets (including the sale of certain intellectual property rights to Galderma S.A.) in the Company's non-GAAP results and the impact from the Company’s internal reorganization / restructuring efforts in 2014, as further described below.

This 2014 sale transaction was included in the Company's U.S.
Rest of the answer

GAAP results as reported in the Company's Form 10-K for the year ended December 31, 2014, but was removed from the Company's non-GAAP results for such period. The tax associated with this gain was also removed from the Company's non-GAAP results for such period. As the tax associated with such gain was significant due to the high U.S. tax rate, the removal of such tax resulted in a lower effective tax rate that was not offset by tax increases on the remaining non-GAAP adjustments, as those adjustments were at significantly lower tax rates. In addition, the GAAP and non-GAAP tax rates for 2014 were benefited by the Company’s internal reorganization / restructuring efforts.

As previously communicated, the Company eliminated the inclusion of the tax effects of the use of tax attributes and other timing items in the calculation of its non-GAAP tax rates. The Company's valuation allowance relates primarily to tax attributes or jurisdictions that are not impacted by non-GAAP adjustments in a material way, and therefore does not impact the Company's non-GAAP tax rates.

The Company has informed us that it acknowledges that:

The Company is responsible for the adequacy and accuracy of the disclosure in the filings;

Staff comments or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filings; and

The Company may not assert the Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Management’s Discussion and Analysis of Financial Condition and Results of Operations · U.S. Healthcare Reform, page 43
SEC asked (1)
The analyses you provide in response to prior comment 2 address your evaluation of the impact of the specified trends/uncertainties on your revenue trends. The guidance in Section III. B of MD&A interpretive release 33-6835 requires the assessment to be made based on the impact on financial condition or results of operations.
Rest of the question

Although, for example, you believe that the anticipated 10% price drop for dermatological and ophthalmological products associated with your Walgreens agreement will not result in a declining revenue trend because of anticipated volume increases, those volume increases could result in relatively higher levels of costs of goods sold and lower gross margins and net income that could be material. Please tell us your consideration of the potential impact on financial condition or results of operations of each of the issues you identified in your response.

BHC answered
Ms. Angela M. Connell

U.S. Securities and Exchange Commission requires the assessment to be made based on the impact on financial condition or results of operations. Although, for example, you believe that the anticipated 10% price drop for dermatological and ophthalmological products associated with your Walgreens agreement will not result in a declining revenue trend because of anticipated volume increases, those volume increases could result in relatively higher levels of costs of goods sold and lower gross margins and net income that could be material.
Rest of the answer

Please tell us your consideration of the potential impact on financial condition or results of operations of each of the issues you identified in your response.

The Company respectfully acknowledges the Staff’s comment. While Valeant’s response dated August 10, 2016 focused on illustrating its consideration of the effect of the implemented and potential price actions on its revenue trends to determine the extent of forward-looking disclosure in the MD&A pursuant to the requirements under Section III. B of MD&A interpretive release 33-6835, the Company also considered the corresponding impact of such price actions would have on its financial condition and results of operations when evaluating the extent of MD&A disclosure. The Company’s consideration of the potential impact on its financial condition or results of operations of each of the identified potential and implemented price actions is outlined below:

Potential and implemented price actions

Analysis

(a) Anticipated price reduction or other anticipated pricing actions (such as discounts or rebates) on the Company’s Isuprel® and Nitropress® products

Given that the Isuprel® and Nitropress® products did not represent a significant portion of the Company’s business (each representing approximately 2% of total revenues for 2015) and given that management did not anticipate any potential increase in volume resulting from the price reductions on those products would result in significant incremental costs given these products have high contribution (being product sales less costs of goods sold, exclusive of amortization and impairments of finite-lived intangible assets, as defined in the Company’s 2015 Form 10-K), management did not believe that the potential net effect from the price reductions on those products and the increase in volume would have a material impact on the Company’s financial condition or results of operations. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

(b) Anticipated price reduction of certain branded prescription-based dermatological and ophthalmologic products that would be sold through the fulfillment programs with Walgreens by, on average, approximately 10 percent

As noted in the Company’s response dated August 10, 2016 and as disclosed in the MD&A in the 2015 Form 10-K, management anticipated the impact of the price reduction would be offset by the impact of the increased volume. Although the increased volume would increase costs of goods sold and certain other costs, the Company did not believe that the incremental costs resulting from the increased volume would be significant because the dermatological and ophthalmologic products that were anticipated to be subject to the price reduction generally generate high contribution. Accordingly, management did not believe that the net impact from the price reduction and the increased volume would have a material impact on the Company’s financial condition or results of operations. As a result, the Company concluded that disclosure of a trend or uncertainty was not necessary.

(c) Potential price controls resulting from legislative action

Given that the adoption of any potential price controls was conjectural and any terms, if adopted, were not known, and were not under management’s control, the Company did not have a basis to evaluate the impact that such actions would have on its overall revenue trend or the corresponding impact on its financial condition or results of operations. Accordingly, the Company concluded that no disclosure of a trend was necessary.

(d) The Company’s intentions with respect to the cessation of or limitation on pricing increases for certain products

As the Company expected that any potential pricing action (other than those imposed by legislative actions) would be made strategically based on, among other things, a price-volume assessment and a cost-benefit evaluation, management did not believe, at the time of the filing of the 2015 Form 10-K and the March 31, 2016 Form 10-Q, that any potential pricing action would have a material impact on the Company’s overall revenue trend or its financial condition and results of operations. Accordingly, the Company concluded that disclosure of a trend or uncertainty was not necessary.

The Company notes that it did refer to the potential impact of the pricing issues described above in its Risk Factors (see pages 14-15, 20, 23, 30, and 31-32) in the Company's 2015 Form 10-K.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Notes to Consolidated Financial Statements · Note 18: Income Taxes, page F-70
SEC asked (2)
We acknowledge your response to prior comment 7. Please address the following additional comments:  Quantify for us the material individual adjustments to tax attributes that result in benefits of $87.1 million in 2015 and $32.3 million in 2014 relative to your statutory tax rate.
Rest of the question

In your response, tell us why these adjustments are appropriately reflected in their respective periods and why they could not have been identified in prior periods.  As the Canadian dollar foreign exchange gain for Canadian tax purposes appears to be related specifically to your U.S. dollar denominated debt, represent to us that you will revise the description of this reconciling item in future Forms 10-K to identify the relationship with that debt.  Explain to us why the change in valuation allowance related to foreign tax credits and net operating losses resulted in a $114.0 million charge in 2015 relative to your statutory rate when the charge in 2014 was only $17.4 million.  Explain to us how the deferral of the tax consequences of intercompany transactions under ASC 740-10-25-3(e) and ASC 810-10-45-8 impacts your effective tax rate when the tax impact of both sides of the transaction is deferred. In your response, explain to us whether you mean that the settlement of the intercompany transaction (either the depreciation/amortization of tangible/intangible assets that removes the basis difference of the asset or the sale of intercompany inventory that results in the reversal of deferred profit in consolidation) when coupled with the differing jurisdictional tax rates between the intercompany parties results in the benefit.  Explain to us why the tax benefit on intra-entity transfers relative to your statutory tax rate is $374.9 million in 2015 and $147.3 million in 2014 when it is only $5.7 million in 2013.

BHC answered
to the third bullet is related to the response to the first bullet, we will address the third bullet next. As noted above, the Company maintains a full valuation allowance against its deferred tax assets related to foreign tax credits and certain state net operating losses within the U.S. Thus, the large increase in the amount of foreign tax credits recorded in 2015 ($91.5 million) compared to 2014 ($30 million) was recorded within the reconciling item for the change in valuation allowance for foreign tax credits.
Rest of the answer

The balance of the change in the valuation allowance for both 2014 and 2015 relates to the Company’s assessment of the realizability of state net operating losses.

1 The balance of the “tax attributes” item relates primarily to a benefit for U.S. R&D credits ($4.2m) and a reduction for limitations on U.S. NOLs ($10.4m).

Securities and Exchange Commission Regulation S-X Rule 4-08(h) requires disclosure of individual reconciling items that are more than five percent of the amount computed by multiplying pretax income by the statutory tax rate. Pursuant to this rule, the Company separately presented the increase in foreign tax credits (and net operating losses) and the associated valuation allowance.

With respect to the second bullet point, the Company agrees that it will amend the title of its rate reconciling item to reflect the Staff's comment to read as follows: "Canadian tax impact of foreign exchange gain or loss on U.S. dollar denominated debt held by VPII and its Canadian Affiliates."

With respect to the fourth bullet point, a significant portion of this item of reconciliation is the result of the Company's internal restructuring efforts (which took place in 2013 and 2014 as disclosed within the Income Tax Footnote of the Company’s Form 10-K for the respective periods) pursuant to which certain assets, including intellectual property (“IP”), were transferred from the U.S. and Barbados to foreign jurisdictions. These transfers were undertaken in a tax-free manner. For local tax purposes, the transfer of the IP resulted in an amortizable step up in tax basis to fair market value, for which no deferred tax asset could be recorded under ASC 740-10-25-3(e). As such, the local tax benefit associated with the amortization is being recognized as incurred pursuant to ASC 740-10-25-3(e).

With respect to the fifth and final bullet point, the tax benefits on intra-entity transfers of $374.9 million in 2015 and $147.3 million in 2014 are primarily related to the transfer of certain assets, including IP, from the U.S. and Barbados to foreign jurisdictions as discussed above and previously disclosed within the Income Tax Footnote of the Company’s Form 10-K for 2013 and 2014. The transfers were part of integration efforts beginning in 2013 and continuing in 2014. In the 2014 presentation of the effective tax rate, the Company presented the “Tax benefit of intra-entity transfers” (i.e., the local tax benefit of amortization) at an amount reflective of the net tax benefit associated with its integration efforts. The Company also presented the difference between the tax rate (i.e., the net tax benefit associated with its integration efforts) on earnings in the jurisdiction in which the IP is owned as compared to the tax on such earnings at the Canadian statutory rate within the “foreign rate differential” line item.

In presenting the tax effect of such items in the 2015 effective tax rate reconciliation, the Company intended to provide greater disclosure transparency within the foreign rate differential line by comparing the tax effect of IP earnings at the Canadian statutory rate versus such earnings at the local statutory rate. Similarly, in 2015, the tax benefit of local tax amortization on the IP assets was presented in the “Tax benefit of intra-entity transfers” line at the local statutory rate rather than at an amount reflective of the net tax benefit of the Company’s integration efforts.

Going forward, the Company will disclose these items in both the 2014 and 2015 effective tax rate reconciliation using the same approach used in 2015. If, in its 2015 Annual Financial Statements, the Company had conformed the 2014 rate reconciliation presentation to the 2015 presentation, the “tax benefit on intra-entity transfers” line item for 2014 would have increased to $420.5 million and the “foreign rate differential” line item would have been reduced to $229.6 million; this is essentially a change in classification between these two line items, with no ultimate change to the total effective tax rate. In other words, using the 2015 presentation, the 2015 “tax benefit on intra-entity transfers” line was $374.9 million as compared to $420.5 million in 2014. The benefit recorded on intra-entity transfers was higher in 2014 compared to 2015 because of other intra-entity transfers for which recording of tax benefits is appropriate. Again, as part of its 2016 Annual Financial Statements, the Company will conform its 2014 presentation and present the 2014, 2015 and 2016 rate reconciliation consistent with the 2015 presentation.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated April 29, 2016 · Reconciliation of GAAP EPS to Adjusted EPS Non-GAAP, Table 2b
SEC asked (3)
We acknowledge your response to prior comment 11. Although the removal of gains and related tax effects from GAAP income in deriving non-GAAP income in 2014 might explain a difference between your GAAP effective tax rate and your non-GAAP effective tax rate in 2014, it does not explain why your effective non-GAAP tax rate in 2014 is lower than those in 2013 or 2015.
Rest of the question

Please address the following additional comments:  Tell us whether there are any other explanations for the lower effective non-GAAP tax rate in 2014 as compared to 2013 other than your internal reorganization/restructuring efforts.  Tell us why your reorganization/restructuring efforts in 2014 do not appear to have a significant continuing impact on your non-GAAP effective tax rate in 2015 as your 2015 rate reverts to a level higher than your 2013 rate.

BHC answered
The Company respectfully acknowledges the Staff's comment. The only explanation for the lower effective non-GAAP tax rates is the internal reorganizations/restructuring efforts. With respect to the second bullet, the Company's restructuring efforts resulted in a jurisdictional mix of earnings that produced a lower non-GAAP effective tax rate in 2014 as compared to 2013.
Rest of the answer

The 2015 acquisition of Salix (as defined below), a company organized under the laws of the United States, changed the Company’s jurisdictional mix of earnings which offset some of the benefit of the Company’s internal restructuring and, thus, increased the non-GAAP effective tax rate in 2015 as compared to 2014.

Exhibit 99.1 Press release dated August 9, 2016

Reconciliations of GAAP EPS to Adjusted EPS Non-GAAP, Tables 2, 2a and 2b

Note related to Staff Comments 4, 5 and 6: The Company respectfully acknowledges the Staff's comments 4, 5 and 6 of the Comment Letter. Prior to responding to each of these items, which relate to the Company’s use of certain non-GAAP measures, the Company wanted to provide some historical context for the use of these measures. Previously, one of the elements of the Company’s business strategy involved business development and the acquisition of companies, businesses and products to expand the Company’s portfolio offering and geographic footprint. As part of this strategy, the Company completed a number of acquisitions each year; however, there was significant variability among these transactions, including the size, nature and frequency of the transactions and the complexity and maturity of the businesses and companies acquired. Consequently, the impact of these transactions on the Company’s reported results varied significantly period to period and made period to period comparisons difficult. As a result, the Company believed the exclusion of certain costs and other amounts relating to such acquisitions allowed a more informative comparison of the financial results from period to period and, therefore, provided useful supplemental information to investors.

Commencing in the later part of 2015 and into 2016, the Company has undergone a number of strategic and organizational changes, as further described below. The Company has revised its business strategy as it relates to business development, such that the Company currently expects the volume and size of its acquisitions to be minimal in 2016 and the foreseeable future. The Company has also experienced significant changes to its executive management team, including the appointment of a new Chief Executive Officer, Chief Financial Officer, Corporate Controller and Chief Accounting Officer and General Counsel. The Company’s Board of Directors has also undergone significant change, with most of the members of its board being replaced at or shortly before its last annual general meeting. In connection with the Board changes, the Company has a predominantly new Audit and Risk Committee.

As a result of these changes to its executive management, Board of Directors (including the Audit Committee) and business strategy and given the current business environment, both as it relates to the Company and more generally, the Company, and its executive management and Board of Directors, are re-evaluating the ways in which the Company views and measures performance and communicates with investors, as well as the purpose and use of its current non-GAAP measures. As a result, the Company’s view on the use of non-GAAP measures (and use of non-GAAP adjustments thereto) is evolving and management anticipates making certain changes to how it calculates and uses non-GAAP measures on a going forward basis, starting fiscal 2017.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated August 9, 2016 · Reconciliations of GAAP EPS to Adjusted EPS Non-GAAP, Tables 2, 2a and 2b
SEC asked (4)
Given the nature and magnitude of the vast majority of your non-GAAP adjustments, it appears that your non-GAAP adjusted net income is actually a non-GAAP liquidity measure. As such, please tell us why this non-GAAP measure is not a liquidity measure or represent to us that you will no longer present this measure on a per share basis.
Rest of the question

Please see Compliance & Disclosure Interpretation on Non-GAAP Financial Measures, or CDI, Question 102.05.

BHC answered
The Company respectfully acknowledges the Staff’s comment. However, the Company believes that non-GAAP adjusted net income is an operating and performance measure and not a liquidity measure.

Non-GAAP adjusted net income has been one of the key metrics in the evaluation of the Company’s performance. In particular, management has used non-GAAP adjusted net income for strategic decision making, forecasting future results, and evaluating current performance and gave guidance on the basis of non-GAAP adjusted earnings per share.
Rest of the answer

In addition, cash bonuses for the Company’s executive officers were based, in part, on the achievement of certain financial targets that were based, partially, on attaining budget or stretch targets for non-GAAP adjusted earnings per share.

Liquidity measures quantify an enterprise's ability to meet its financial obligations as they come due, both on a short and long term basis. The Company uses GAAP cash flows from operations as its liquidity measure. The Company's primary sources of liquidity are its cash on hand, cash flows generated from its operations, funds available from its revolving credit facility, issuances of long-term debt and issuances of equity or equity-linked securities, and, in certain circumstances, cash from divestitures.

Non-GAAP adjusted net income excludes the impact of certain items that management believes may obscure important trends in the Company’s underlying performance. By disclosing this non-GAAP measure, management intended to provide investors with a meaningful, supplemental comparison of the Company’s operating results and trends for the periods presented. Management believes this measure is also useful to investors because it allows investors to evaluate the Company’s performance using the same tools that management uses to evaluate past performance and prospects for the Company’s future performance. Accordingly, the Company believes that non-GAAP adjusted net income is useful to investors in their assessment of the Company’s operating performance and the valuation of the Company.

The distinction between non-GAAP adjusted net income as a performance measure and GAAP cash flows from operations as a liquidity measure is reflected in the differences in the nature and the type of adjustments that are made in calculating these measures. In calculating the GAAP cash flows from operations, the Company adjusted GAAP net income by all non-cash items in GAAP net income, as well as the effects of all deferrals of past operating cash receipts and payments and all accruals of expected future operating cash receipts and payments. In contrast, the Company’s calculation of non-GAAP adjusted net income adjusts for items, both cash and non-cash, that varied meaningfully in nature and amount from period to period and may obscure important trends in the Company’s underlying performance. Importantly, adjusted net income (a) did not exclude all non-cash items included in GAAP net income (for example, it did not exclude depreciation expense exclusive of fair value step-up/down from purchase accounting, allowances for losses on accounts receivable and inventories, stock-based compensation exclusive of the effect of acceleration of vesting of certain equity awards, income tax provision exclusive of income tax effect relating to non-GAAP adjustments) and did not adjust for the effects of deferral of cash receipts and payments and (b) at the same time, excluded certain items with a cash impact (for example, acquired in-process research and development, restructuring, integration, acquisition-related and other costs, and legal settlement costs). In addition, based on the Company’s calculation of non-GAAP adjusted net income, more adjustments are required to reconcile non-GAAP adjusted net income to cash flows from operations than are required to reconcile non-GAAP adjusted net income to net income calculated in accordance with GAAP.

Accordingly, the Company believes that non-GAAP adjusted net income is a performance measure and not a liquidity measure.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated August 9, 2016 · Reconciliations of GAAP EPS to Adjusted EPS Non-GAAP, Tables 2, 2a and 2b
SEC asked (5)
Please explain to us why it is appropriate to remove restructuring, integration and deal costs, termination of certain supply and distribution agreements costs and legal settlement and legal proceedings, investigations and inquiries costs from your adjusted non-GAAP income measure when they appear to be normal, recurring operating expenses that will be settled in cash. See CDI 100.01.
Rest of the question

In your response, please tell us the significant components of each of the expenses for each of the last three years and the latest interim periods with comparable amounts for the 2015 interim period.

BHC answered
The Company respectfully acknowledges the Staff’s comment. The Company believes that (a) restructuring, integration and deal costs, (b) termination of certain supply and distribution agreements costs and (c) legal settlement and legal proceedings, investigations and inquiries costs were each appropriate adjustments to GAAP net income in determining the Company’s non-GAAP results.
Rest of the answer

As further described below, given the variability and volatility of the amount and/or frequency of these costs, the Company believes that these costs were not normal operating expenses and, by adjusting these costs, it provided useful supplemental information to investors.

(a)

Restructuring, Integration and Deal Costs

The Company believes it was appropriate to remove restructuring, integration and deal costs from its calculation of adjusted net income because it did not view these costs as normal, recurring operating expenses. When the Company completed acquisitions, they resulted in expenses which varied significantly from period to period and would not otherwise have been incurred. The Company has excluded these restructuring, integration and other acquisition-related expense items resulting from these acquisitions in calculating non-GAAP adjusted net income. The significant components of these acquisition-related expenses were the following: (i) employee severance costs, (ii) costs associated with contract terminations, (iii) payments to integration consultants and external advisors (i.e., deal counsel), (iv) reduction of duplicative labor costs, and (v) costs to close facilities and integrate manufacturing capabilities. In addition, for two acquisitions, which were consummated in Q2 2013 and Q1 2014, the Company also excluded stock based compensation related to accelerated vesting of the acquired business’s unvested stock-based awards on the date of acquisition (please note that the Company currently presents these expenses in Other income/expense within operating income and, at the time when the Company changed its presentation policy, the amounts described above were not reclassified due to their immaterial nature). During the period beginning January 1, 2013 and ending on June 30, 2016, the most significant transactions to which the expenses described above related were the acquisitions of Bausch & Lomb Holdings Incorporated, Medicis Pharmaceutical Corporation and Salix Pharmaceuticals, Ltd. (“Salix”).

The type, nature, size and frequency of the Company’s acquisitions have varied considerably period to period. As a result, the type and amount of the restructuring, integration and deal costs have also varied significantly from acquisition to acquisition. In addition, the costs associated with an acquisition varied significantly from quarter to quarter, with most costs generally decreasing over time. Consequently, given the variability and volatility of these costs from acquisition to acquisition and period to period and because these costs are incremental and directly related to the acquisition, the Company does not view these costs as normal operating expenses.

Furthermore, due to the volatility of these costs and due to the fact that they are directly related to the acquisitions, the Company believes that such costs generally were not relevant to assessing or estimating the long-term performance of the acquired businesses or assets as part of the Company. In addition, as described above, the frequency and amount of such charges varied significantly from period to period based on the size and timing of the acquisitions and the maturities of the businesses being acquired. Also, the size, complexity and/or volume of past acquisitions, which often drove the magnitude of such expenses, were not necessarily indicative of the size, complexity and/or volume of any future acquisitions. By excluding these expenses from its non-GAAP measures, management believes it provided supplemental information that assisted investors with their evaluation of the Company’s ability to utilize its existing assets and with its estimation of the long-term value that acquired assets would generate for the Company. Furthermore, the Company believes that the adjustments of these items provided supplemental information with regard to the sustainability of the Company’s operating performance, allowed a more informative comparison of the financial results to historical operations and forward-looking guidance and, as a result, provided useful supplemental information to investors.

(b)

Termination of Certain Supply and Distribution Agreements Costs

The Company believes it was appropriate to remove these costs because it believes such costs were not normal, recurring operating costs. These adjustments relate to three arrangements between the Company and certain third parties for product distribution, promotion or other commercialization. In particular, the costs relate to charges that were taken in connection with the cessation of the particular product commercialization or the arrangements themselves. The Company excluded such costs in calculating non-GAAP adjusted net income in the fourth quarter of 2015 (in an aggregate amount of $20.6 million), with a $1.4 million true-up in the first quarter of 2016. Each of these costs was individually immaterial. There were no such charges in 2013 or 2014 or the remainder of 2015 or 2016 (to date).

Given the nature and frequency of these costs, the Company does not consider these to be normal, recurring operating costs. The Company does not anticipate that it will be making similar adjustments on a going-forward basis and, in future filings, the Company would provide supplemental disclosure to explain the impact of such change.

(c)

Legal Settlement and Legal Proceedings, Investigations and Inquiries Costs

During the period from January 1, 2013 to June 30, 2016, the Company excluded the costs associated with its legal settlements and judgments and the costs associated with certain legal proceedings, investigations and inquiries, as further described below, because the Company believes such costs were not normal operating expenses.

In regard to legal settlements and judgments, during the period from January 1, 2013 to June 30, 2016, the most significant components of these costs were as follows: (i) in 2013, there was an $142.5 million charge that related to a settlement with Anacor Pharmaceuticals, Inc. (“Anacor”), which resolved all outstanding breach of contract disputes between Anacor and Valeant and its affiliates; (ii) in 2013, following an unfavorable court decision, a $50 million charge was recorded relating to litigation respecting a claim for lost profits for alleged violation of Russian competition law in connection with the registration by Valeant’s subsidiary, Natur Produkt, of its AntiGrippin trademark. Subsequently, in 2014, the $50 million charge was reversed following a favorable appeal decision and, in 2015, a new charge of $25.4 million was recorded for this matter, after a further appeal court required Natur Produkt to pay $25.4 million; and (iii) in 2016, there was a favorable adjustment relating to a reduction in liability of approximately $39.4 million relating to the execution of a settlement agreement with the United States, which settled the federal claims against Salix relating to its sales and promotional practices for its Xifaxan®, Relistor® and Apriso® products (this reduction was made following a re-assessment of the Company's legal liability, which was initially measured at fair value on the date of the Salix acquisition). Legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. By excluding these amounts, the Company believes it provided supplemental information to investors to assist in the comparison of its financial results from period to period.

In addition to the costs related to legal settlements and judgments, the Company also excluded costs associated with certain recent legal and governmental proceedings, investigations and information requests relating primarily to certain of its distribution, pricing, disclosure and accounting practices. As opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests (the significant components of which are described in more detail below), given their nature and frequency, are outside of the ordinary course and relate to unique circumstances that are not expected to occur again. In particular, during the fourth quarter of 2015 and the first and second quarters of 2016, the Company excluded the costs associated with various legal and governmental proceedings, investigations and information requests relating to the Company’s distribution, marketing, pricing, pharmacy, disclosure and accounting practices (including with respect to its former relationship with Philidor Rx Services, LLC (“Philidor”)). During this time period, the Company also excluded the costs associated with the review by the ad hoc committee of independent directors of the Board of Directors, which was established to review allegations regarding the Company’s relationship with Philidor and related matters. Finally, the Company also excluded certain costs associated with the termination of its arrangements with Philidor. In the aggregate, these costs equaled $7.4 million in the fourth quarter of 2015, $27.5 million in the first quarter of 2016 and $9.5 million in the second quarter of 2016.

As indicated above, given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. Furthermore, the Company believes that the exclusion of such out of the ordinary course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated August 9, 2016 · Reconciliations of GAAP EPS to Adjusted EPS Non-GAAP, Tables 2, 2a and 2b
SEC asked (6)
Please explain to us why it is appropriate to remove only portions of your depreciation expense (associated with the fair value step-up in acquisition accounting) and share-based compensation from your non-GAAP income measure.
Rest of the question

In your response, tell us your consideration of why your resulting non-GAAP income measure does not incorporate these expenses under individually tailored expense recognition methods precluded under the guidance in CDI 100.04.

BHC answered
The Company respectfully acknowledges the Staff's comment, but believes that its treatment of depreciation expense associated with the fair value step-up in acquisition accounting, as well as its share-based compensation, in each case during the periods covered by the press release dated August 9, 2016 attached to its Form 8-K dated August 9, 2016, were not individually tailored expense recognition methods that were in violation of Rule 100(b) of Regulation G and therefore precluded under the Staff's guidance in CDI 100.04.
Rest of the answer

By excluding these impacts, the Company was able to provide supplemental information with respect to the comparison of the performance of the Company from period to period. The Company has evaluated its treatment of these items and has made a determination that, on a going-forward basis, it does not anticipate making such adjustments when calculating non-GAAP adjusted net income and, in future filings, the Company would provide supplemental disclosure to explain the impact of such change.

First, with respect to such depreciation expense, the Company excluded the impact of fair value step-up/down adjustments to property, plant & equipment in connection with business combinations. The Company believes it was appropriate to do so, because the amount and the frequency of the adjustments were significantly impacted by the timing and size of the Company's acquisitions, as well as the structure of the acquisitions (acquisition of shares versus assets or inclusion versus exclusion of capital assets) and the operating strategy of the acquired businesses with respect to the level of investment in capital assets inherited by the Company as part of those acquisitions. By excluding these impacts, the Company was able to report a non-GAAP adjusted net income figure from period to period that was not impacted by the variability driven by purchase accounting and gave investors supplemental information with respect to the comparison of the performance of the

Company from period to period. While the Company believes it was appropriate to adjust out these particular depreciation costs, it does not believe it was appropriate to adjust out all other depreciation costs, because those costs were part of the normal operating performance of the Company from period to period.

Second, with respect to share-based compensation, there were two components during the applicable period: (i) primarily, the share-based compensation directly attributable to the termination of the Company’s former Chief Executive Officer and Chief Financial Officer, and (ii) to a lesser extent, the impact of accelerated vesting of certain performance-based share-based equity instruments (“PSUs”) directly triggered by stock price appreciation. Regarding the first and more material component, the Company believes that the termination impact was not a normal, recurring operating expense and that the inclusion of such item would obscure the trend of the Company’s operating performance. With respect to the second and less material component, the Company excluded the effect because it was solely triggered by the attainment of certain stock price-based performance targets. Given the volatility of the Company’s stock price (over which the Company has no control and which is driven by various factors such as the announcement of acquisitions by the Company), the effect of such acceleration was excluded. While the Company believes it was appropriate to adjust out volatilities in share-based compensation costs due to the acceleration of vesting of the PSUs, it does not believe it was appropriate to adjust out all other share-based compensation costs, because those costs were part of the normal operating performance of the Company from period to period.

Read in the reply
In its next report

First report after the company's reply of Oct 6, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1 Press release dated August 9, 2016 · Reconciliations of GAAP EPS to Adjusted EPS Non-GAAP, Tables 2, 2a and 2b
SEC asked
You indicate in response to prior comment 4 that you use non-GAAP adjusted net income as an operating and performance measure and not as a liquidity measure. Question 102.05 of the updated Non-GAAP Compliance and Disclosure Interpretations made clear, however, that whether per share data is prohibited depends on whether the non-GAAP measure can be used as a liquidity measure, not on how management chooses to
Rest of the question

characterize it. Your non-GAAP measure bears a striking resemblance to your cash flows and differs drastically, including directionally, from your GAAP net income. For example, your non-GAAP net income was $487.5 million for the three months ended June 30, 2016 and your “GAAP cash flow from operations” were $448.1 million. In order to convert your GAAP net loss of $302.3 million to non-GAAP net income, you eliminated almost $800 million of mostly non-cash charges. The relationship of your non-GAAP net income to cash flows was further strengthened by the fact that, until making a change in response to staff comment issued last year, you referred to your non- GAAP measure as “cash earnings.” We believe that your per share presentation is inconsistent with both Commission and staff guidance and should be discontinued.

BHC answered
We respectfully acknowledge the Staff’s comment. As was indicated in our response letter dated October 6, 2016, the Company is undergoing various changes, including transition to a new management team. Our new management is committed to making certain changes to how it calculates and uses non-GAAP measures to ensure that our non-GAAP measures best reflect the underlying financial performance of the business and are consistent with the Staff’s guidance on this issue.
Rest of the answer

In light of this, we confirm that, in conjunction with these changes, we will, in the future, revise our earnings releases as discussed below to discontinue the use of the per share presentation of our non-GAAP adjusted net income measure, as it is currently calculated (and replace this measure as further described below).

In terms of the timing of this change, we note that our published full-year 2016 guidance includes this non-GAAP adjusted net income per share component. Accordingly, the Company believes that to eliminate its current practice for its third quarter earnings release would be confusing to its investors and potentially result in a significant disruption in the market. Therefore, the Company believes it is more appropriate to make the changes to non-GAAP adjusted net income per share in connection with the release of our 2017 guidance. This will also align with the timing of our other anticipated changes to our non-GAAP measures. This will allow us to fully explain to our investors our updated views on performance measures and present to them our revised use of non-GAAP measures in their entirety. The Company believes that explaining and presenting all changes at the same time (as opposed to incrementally over two quarters) will allow for a better understanding by investors and less confusion and disruption in the market.

As part of the re-assessment of our non-GAAP measures, we will revise the presentation to disclose a modified non-GAAP adjusted net income measure, which we intend to present on a per share basis. We are working with our advisors to establish the appropriate adjustments to arrive at this measure and are taking into account the SEC’s recent guidance on this topic and the comments received from the Staff in its recent letters to, and discussions with, the Company.

Once this new measure has been established, we would propose to use that measure to present our full-year 2017guidance. We would also present our 2016 fourth quarter and full-year results using this new metric to create a baseline comparison for 2017 results, and, for a final time, present our 2016 results using this non-GAAP adjusted net income metric, as calculated on the present basis, to allow investors to assess our performance on the basis of the previously published 2016 guidance.

Read in the reply
In its next report

First report after the company's reply of Oct 28, 2016: 10-Q filed Nov 9, 2016 ↗, against the 10-Q filed Jun 7, 2016 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: request for more time, Jul 26, 2016, request for more time, Sep 21, 2016, closing letter, 2016-10-31

SEC enforcement releases naming BHC

Litigation releases and accounting and auditing enforcement releases (AAER) · sec.gov

1

A release is listed only when SEC's list names Bausch Health Companies Inc. (or a name it had before) among those the action is against. The page does not say what the release found: open it on sec.gov. A release against a person at the company, or one that names the company under another spelling, is not matched, so this list can be shorter than SEC's.

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 12 letters filed since 2016-07-13. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BHC/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.